| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.541 | 0.013 | 0.541 | Antiamyloidogenic | 0.407 0.027 DBMET00290 | ||
| 0.52 | 0.012 | 0.52 | Amyloid beta aggregation inhibitor | 0.391 0.026 DBMET00290 | ||
| 0.515 | 0.031 | 0.515 | Aldehyde oxidase inhibitor | 0.314 0.063 DBMET00290 | ||
| 0.455 | 0.002 | 0.455 | Histamine N-methyltransferase inhibitor | 0.251 0.004 DBMET00290 | ||
| 0.414 | 0.004 | 0.414 | Potassium channel (Ca-activated) activator | 0.303 0.005 DBMET00290 | ||
| 0.44 | 0.083 | 0.475 | MAP kinase 1 inhibitor | 0.475 0.064 DBMET00290 | DBMET00290 | |
| 0.332 | 0.026 | 0.335 | ErbB-1 antagonist | 0.335 0.025 DBMET00290 | DBMET00290 | |
| 0.291 | 0.03 | 0.291 | DNA methylase inhibitor | 0.254 0.046 DBMET00290 | ||
| 0.284 | 0.032 | 0.284 | DNA methyltransferase I inhibitor | 0.244 0.05 DBMET00290 | ||
| 0.263 | 0.011 | 0.263 | ATPase inhibitor | 0.195 0.042 DBMET00290 | ||
| 0.262 | 0.018 | 0.262 | Acetylcholinesterase inhibitor | 0.143 0.059 DBMET00290 | ||
| 0.271 | 0.045 | 0.293 | MAP kinase kinase 2 inhibitor | 0.293 0.037 DBMET00290 | DBMET00290 | |
| 0.297 | 0.08 | 0.297 | Caspase 3 stimulant | 0.218 0.145 DBMET00290 | ||
| 0.235 | 0.019 | 0.235 | Chelator | 0.146 0.037 DBMET00290 | ||
| 0.226 | 0.022 | 0.226 | Cyclin-dependent kinase 3 inhibitor | 0.177 0.052 DBMET00290 | ||
| 0.297 | 0.095 | 0.311 | Calcium channel activator | 0.311 0.081 DBMET00290 | DBMET00290 | |
| 0.233 | 0.033 | 0.235 | Heat shock protein 90 alpha antagonist | 0.235 0.032 DBMET00290 | DBMET00290 | |
| 0.286 | 0.088 | 0.287 | 12-Lipoxygenase inhibitor | 0.287 0.087 DBMET00290 | DBMET00290 | |
| 0.225 | 0.036 | 0.225 | Cholinergic | |||
| 0.2 | 0.038 | 0.2 | Heat shock protein 90 antagonist | 0.193 0.041 DBMET00290 | ||
| 0.182 | 0.025 | 0.182 | Butyrylcholinesterase inhibitor | 0.107 0.056 DBMET00290 | ||
| 0.194 | 0.04 | 0.194 | Death-associated protein kinase 2 inhibitor | 0.179 0.055 DBMET00290 | ||
| 0.226 | 0.073 | 0.226 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.18 0.107 DBMET00290 | ||
| 0.285 | 0.14 | 0.285 | 15-Lipoxygenase inhibitor | |||
| 0.152 | 0.01 | 0.152 | Potassium channel large-conductance Ca-activated activator | 0.113 0.019 DBMET00290 | ||
| 0.197 | 0.056 | 0.197 | Src kinase inhibitor | 0.187 0.061 DBMET00290 | ||
| 0.175 | 0.035 | 0.175 | Epidermal growth factor receptor kinase inhibitor | 0.168 0.038 DBMET00290 | ||
| 0.153 | 0.018 | 0.153 | CC chemokine 6 receptor antagonist | 0.151 0.02 DBMET00290 | ||
| 0.189 | 0.054 | 0.189 | Protein kinase (CK1) gamma 3 inhibitor | 0.183 0.058 DBMET00290 | ||
| 0.311 | 0.182 | 0.315 | Caspase 9 stimulant | 0.315 0.178 DBMET00290 | DBMET00290 | |
| 0.242 | 0.114 | 0.242 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | |||
| 0.161 | 0.039 | 0.161 | Aurora-C kinase inhibitor | 0.147 0.053 DBMET00290 | ||
| 0.145 | 0.027 | 0.145 | Beta glucuronidase inhibitor | 0.098 0.072 DBMET00290 | ||
| 0.119 | 0.007 | 0.119 | Topoisomerase II beta inhibitor | 0.084 0.012 DBMET00290 | ||
| 0.161 | 0.05 | 0.161 | c-Src kinase inhibitor | 0.154 0.053 DBMET00290 | ||
| 0.134 | 0.024 | 0.136 | MAP kinase kinase 1 inhibitor | 0.136 0.023 DBMET00290 | DBMET00290 | |
| 0.118 | 0.012 | 0.118 | 5 Hydroxytryptamine 5A antagonist | 0.098 0.016 DBMET00290 | ||
| 0.117 | 0.012 | 0.117 | 5 Hydroxytryptamine 5 antagonist | 0.105 0.014 DBMET00290 | ||
| 0.132 | 0.028 | 0.132 | Electrolyte absorption antagonist | 0.11 0.046 DBMET00290 | ||
| 0.251 | 0.154 | 0.263 | GABA C receptor rho-3 antagonist | 0.263 0.143 DBMET00290 | DBMET00290 | |
| 0.147 | 0.053 | 0.173 | MAP kinase kinase inhibitor | 0.173 0.04 DBMET00290 | DBMET00290 | |
| 0.136 | 0.044 | 0.136 | Interleukin 8 antagonist | 0.124 0.056 DBMET00290 | ||
| 0.17 | 0.08 | 0.175 | LIM domain kinase 1 inhibitor | 0.175 0.077 DBMET00290 | DBMET00290 | |
| 0.181 | 0.092 | 0.181 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | |||
| 0.16 | 0.073 | 0.16 | Peroxidase inhibitor | 0.141 0.083 DBMET00290 | ||
| 0.152 | 0.066 | 0.152 | Activin receptor-like kinase 2 inhibitor | |||
| 0.143 | 0.057 | 0.143 | Interleukin 4 antagonist | 0.139 0.061 DBMET00290 | ||
| 0.17 | 0.085 | 0.17 | MAP kinase kinase 5 inhibitor | |||
| 0.1 | 0.016 | 0.121 | Potassium channel (ATP-sensitive) blocker | 0.121 0.009 DBMET00290 | DBMET00290 | |
| 0.092 | 0.012 | 0.121 | Botulinum neurotoxin type A inhibitor | 0.121 0.006 DBMET00290 | DBMET00290 | |
| 0.148 | 0.071 | 0.157 | MAP kinase 3 inhibitor | 0.157 0.057 DBMET00290 | DBMET00290 | |
| 0.104 | 0.03 | 0.126 | Myeloperoxidase inhibitor | 0.126 0.017 DBMET00290 | DBMET00290 | |
| 0.093 | 0.025 | 0.098 | Transforming growth factor antagonist | 0.098 0.022 DBMET00290 | DBMET00290 | |
| 0.102 | 0.035 | 0.12 | Vanilloid antagonist | 0.12 0.028 DBMET00290 | DBMET00290 | |
| 0.171 | 0.105 | 0.171 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.157 0.123 DBMET00290 | ||
| 0.099 | 0.036 | 0.105 | ErbB-2 antagonist | 0.105 0.033 DBMET00290 | DBMET00290 | |
| 0.185 | 0.123 | 0.2 | MAP-kinase-activated kinase 5 inhibitor | 0.2 0.103 DBMET00290 | DBMET00290 | |
| 0.127 | 0.067 | 0.127 | Glutamate receptor antagonist | 0.119 0.075 DBMET00290 | ||
| 0.073 | 0.017 | 0.073 | Transforming growth factor beta 1 antagonist | 0.073 0.018 DBMET00290 | ||
| 0.1 | 0.045 | 0.1 | Epidermal growth factor antagonist | 0.098 0.046 DBMET00290 | ||
| 0.115 | 0.06 | 0.115 | EphA2 antagonist | 0.11 0.065 DBMET00290 | ||
| 0.119 | 0.065 | 0.119 | Aurora-B kinase inhibitor | 0.095 0.088 DBMET00290 | ||
| 0.134 | 0.08 | 0.134 | Growth factor antagonist | 0.131 0.083 DBMET00290 | ||
| 0.11 | 0.056 | 0.11 | Ephrin antagonist | 0.103 0.061 DBMET00290 | ||
| 0.261 | 0.212 | 0.261 | 5 Hydroxytryptamine release inhibitor | |||
| 0.136 | 0.088 | 0.136 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.13 0.094 DBMET00290 | ||
| 0.2 | 0.152 | 0.2 | Hypoxia-inducible factor 1 alpha inhibitor | |||
| 0.164 | 0.117 | 0.164 | EphB2 antagonist | 0.157 0.122 DBMET00290 | ||
| 0.17 | 0.123 | 0.17 | Free radical scavenger | 0.155 0.14 DBMET00290 | ||
| 0.186 | 0.142 | 0.186 | Streptokinase A inhibitor | 0.164 0.159 DBMET00290 | ||
| 0.152 | 0.108 | 0.152 | Succinate dehydrogenase inhibitor | 0.151 0.11 DBMET00290 | ||
| 0.156 | 0.113 | 0.156 | Death-associated protein kinase 3 inhibitor | 0.151 0.12 DBMET00290 | ||
| 0.095 | 0.054 | 0.105 | Potassium channel activator | 0.105 0.043 DBMET00290 | DBMET00290 | |
| 0.056 | 0.018 | 0.056 | Benzodiazepine antagonist | |||
| 0.12 | 0.085 | 0.12 | Protein-tyrosine kinase Lyn inhibitor | 0.106 0.097 DBMET00290 | ||
| 0.11 | 0.077 | 0.134 | Topoisomerase II inhibitor | 0.134 0.058 DBMET00290 | DBMET00290 | |
| 0.172 | 0.14 | 0.172 | Antioxidant | |||
| 0.092 | 0.061 | 0.117 | Protein kinase C zeta inhibitor | 0.117 0.034 DBMET00290 | DBMET00290 | |
| 0.063 | 0.032 | 0.063 | Protein kinase C theta inhibitor | 0.062 0.033 DBMET00290 | ||
| 0.119 | 0.089 | 0.119 | Interleukin 1 antagonist | |||
| 0.041 | 0.013 | 0.041 | Benzodiazepine receptor peripheral-type antagonist | |||
| 0.091 | 0.063 | 0.091 | ABCA1 expression enhancer | |||
| 0.171 | 0.144 | 0.171 | DNA damaging | |||
| 0.05 | 0.024 | 0.05 | Potassium channel small-conductance Ca-activated blocker | |||
| 0.086 | 0.06 | 0.086 | Insulin growth factor antagonist | |||
| 0.074 | 0.049 | 0.074 | Telomerase inhibitor | 0.067 0.055 DBMET00290 | ||
| 0.137 | 0.112 | 0.138 | CDC-like kinase 4 inhibitor | 0.138 0.111 DBMET00290 | DBMET00290 | |
| 0.043 | 0.019 | 0.06 | DNA gyrase subunit B inhibitor | 0.06 0.009 DBMET00290 | DBMET00290 | |
| 0.062 | 0.038 | 0.062 | Potassium channel (Ca-activated) blocker | |||
| 0.144 | 0.12 | 0.144 | Clk dual-specificity kinase inhibitor | |||
| 0.122 | 0.099 | 0.122 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | |||
| 0.142 | 0.12 | 0.142 | Ca2+/calmodulin-dependent protein kinase inhibitor | |||
| 0.082 | 0.059 | 0.085 | Transforming growth factor beta 3 antagonist | 0.085 0.05 DBMET00290 | DBMET00290 | |
| 0.112 | 0.092 | 0.112 | Lck kinase inhibitor | |||
| 0.082 | 0.063 | 0.082 | NMDA receptor antagonist | 0.076 0.071 DBMET00290 | ||
| 0.032 | 0.014 | 0.045 | MAP3K8 inhibitor | 0.045 0.005 DBMET00290 | DBMET00290 | |
| 0.114 | 0.097 | 0.114 | Protein kinase (CK1) gamma inhibitor | 0.109 0.104 DBMET00290 | ||
| 0.11 | 0.094 | 0.12 | Glycogen synthase kinase-3 alpha inhibitor | 0.12 0.085 DBMET00290 | DBMET00290 | |
| 0.057 | 0.042 | 0.057 | EphB4 antagonist | |||
| 0.078 | 0.064 | 0.078 | Insulin like growth factor 1 antagonist | |||
| 0.141 | 0.128 | 0.141 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.14 0.13 DBMET00290 | ||
| 0.089 | 0.076 | 0.107 | Alpha 2c adrenoreceptor antagonist | 0.107 0.06 DBMET00290 | DBMET00290 | |
| 0.072 | 0.06 | 0.085 | Topoisomerase II alpha inhibitor | 0.085 0.05 DBMET00290 | DBMET00290 | |
| 0.191 | 0.18 | 0.218 | Angiogenesis inhibitor | 0.218 0.15 DBMET00290 | DBMET00290 | |
| 0.149 | 0.137 | 0.149 | Dyrk kinase inhibitor | 0.145 0.141 DBMET00290 | ||
| 0.114 | 0.104 | 0.114 | Protein kinase (CK1) gamma 1 inhibitor | |||
| 0.066 | 0.056 | 0.066 | NMDA 2 receptor antagonist | 0.065 0.057 DBMET00290 | ||
| 0.068 | 0.058 | 0.068 | Porphobilinogen synthase inhibitor | |||
| 0.066 | 0.056 | 0.066 | CXC chemokine receptor antagonist | |||
| 0.048 | 0.039 | 0.051 | H+/K+-transporting ATPase inhibitor | 0.051 0.035 DBMET00290 | DBMET00290 | |
| 0.124 | 0.115 | 0.124 | CDC-like kinase 2 inhibitor | |||
| 0.059 | 0.052 | 0.061 | CDC25B inhibitor | 0.061 0.049 DBMET00290 | DBMET00290 | |
| 0.101 | 0.096 | 0.112 | RET inhibitor | 0.112 0.085 DBMET00290 | DBMET00290 | |
| 0.082 | 0.078 | 0.083 | Platelet activating factor alpha antagonist | 0.083 0.077 DBMET00290 | DBMET00290 | |
| 0.13 | 0.127 | 0.13 | Amyloid beta precursor protein antagonist | |||
| 0.089 | 0.087 | 0.089 | DNA intercalator | |||
| 0.065 | 0.064 | 0.081 | Rho-associated kinase II inhibitor | 0.081 0.044 DBMET00290 | DBMET00290 | |
| 0.039 | 0.038 | 0.039 | Liver X receptor agonist | |||
| 0.051 | 0.051 | 0.054 | Raf kinase C inhibitor | 0.054 0.048 DBMET00290 | DBMET00290 | |
| 0.034 | 0.035 | 0.04 | Potassium channel Kv1.1 blocker | 0.04 0.023 DBMET00290 | DBMET00290 | |
| 0.055 | 0.062 | 0.065 | Vanilloid 1 antagonist | 0.065 0.048 DBMET00290 | DBMET00290 | |
| 0.105 | 0.112 | 0.112 | Vascular endothelial growth factor 3 antagonist | 0.112 0.103 DBMET00290 | DBMET00290 | |
| 0.08 | 0.088 | 0.128 | MAP kinase kinase kinase inhibitor | 0.128 0.046 DBMET00290 | DBMET00290 | |
| 0.056 | 0.071 | 0.067 | MAP kinase kinase 10 inhibitor | 0.067 0.045 DBMET00290 | DBMET00290 | |
| 0.064 | 0.084 | 0.122 | Adrenaline agonist | 0.122 0.025 DBMET00290 | DBMET00290 | |
| 0.074 | 0.095 | 0.084 | Bromodomain-containing protein 2 inhibitor | 0.084 0.068 DBMET00290 | DBMET00290 | |
| 0.038 | 0.059 | 0.049 | Protein kinase C epsilon inhibitor | 0.049 0.042 DBMET00290 | DBMET00290 | |
| 0.071 | 0.098 | 0.146 | Aminoacyl-tRNA synthetase inhibitor | 0.146 0.02 DBMET00290 | DBMET00290 | |
| 0.111 | 0.141 | 0.137 | Polo-like kinase-3 inhibitor | 0.137 0.099 DBMET00290 | DBMET00290 | |
| 0.046 | 0.079 | 0.112 | DNA gyrase inhibitor | 0.112 0.015 DBMET00290 | DBMET00290 | |
| 0.173 | 0.215 | 0.204 | 5 Hydroxytryptamine uptake stimulant | 0.204 0.143 DBMET00290 | DBMET00290 | |
| 0.041 | 0.084 | 0.06 | MAP kinase kinase 9 inhibitor | 0.06 0.031 DBMET00290 | DBMET00290 | |
| 0.088 | 0.135 | 0.111 | NADPH oxidase inhibitor | 0.111 0.095 DBMET00290 | DBMET00290 | |
| 0.143 | 0.199 | 0.181 | Superoxide dismutase inhibitor | 0.181 0.14 DBMET00290 | DBMET00290 | |
| 0.051 | 0.107 | 0.062 | Beta 2 adrenoreceptor agonist | 0.062 0.04 DBMET00290 | DBMET00290 | |
| 0.041 | 0.101 | 0.058 | Alpha adrenoreceptor agonist | 0.058 0.057 DBMET00290 | DBMET00290 | |
| 0.15 | 0.212 | 0.182 | Nitric-oxide synthase stimulant | 0.182 0.124 DBMET00290 | DBMET00290 | |
| 0.094 | 0.187 | 0.114 | Papain-like protease (SARS coronavirus) inhibitor | 0.114 0.098 DBMET00290 | DBMET00290 | |
| 0.092 | 0.204 | 0.122 | GABA C receptor rho-2 antagonist | 0.122 0.121 DBMET00290 | DBMET00290 | |
| 0.083 | 0.224 | 0.134 | Neuropeptide Y1 antagonist | 0.134 0.092 DBMET00290 | DBMET00290 | |
| 0.05 | 0.268 | 0.086 | Ca(v)3.1 blocker | 0.086 0.044 DBMET00290 | DBMET00290 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |